

# M Elizabeth Halloran

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3892899/publications.pdf>

Version: 2024-02-01

103  
papers

11,268  
citations

109137

35  
h-index

38300

95  
g-index

115  
all docs

115  
docs citations

115  
times ranked

14781  
citing authors

#	ARTICLE	IF	CITATIONS
1	The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. <i>Science</i> , 2020, 368, 395-400.	6.0	2,784
2	Containing Pandemic Influenza at the Source. <i>Science</i> , 2005, 309, 1083-1087.	6.0	1,044
3	Antibody-dependent enhancement of severe dengue disease in humans. <i>Science</i> , 2017, 358, 929-932.	6.0	800
4	Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19. <i>Nature Human Behaviour</i> , 2020, 4, 964-971.	6.2	605
5	Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 793-802.	4.6	541
6	Toward Causal Inference With Interference. <i>Journal of the American Statistical Association</i> , 2008, 103, 832-842.	1.8	456
7	Containing Bioterrorist Smallpox. <i>Science</i> , 2002, 298, 1428-1432.	6.0	324
8	Zika virus evolution and spread in the Americas. <i>Nature</i> , 2017, 546, 411-415.	13.7	323
9	Aggregated mobility data could help fight COVID-19. <i>Science</i> , 2020, 368, 145-146.	6.0	303
10	Assessing the International Spreading Risk Associated with the 2014 West African Ebola Outbreak. <i>PLOS Currents</i> , 2014, 6, .	1.4	251
11	Spread of Zika virus in the Americas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4334-E4343.	3.3	249
12	Spatiotemporal spread of the 2014 outbreak of Ebola virus disease in Liberia and the effectiveness of non-pharmaceutical interventions: a computational modelling analysis. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 204-211.	4.6	226
13	Causal Inference in Infectious Diseases. <i>Epidemiology</i> , 1995, 6, 142-151.	1.2	209
14	Study Designs for Dependent Happenings. <i>Epidemiology</i> , 1991, 2, 331-338.	1.2	198
15	Design and Analysis of Vaccine Studies. <i>Statistics in the Health Sciences</i> , 2010, , .	0.2	189
16	Zika virus infection enhances future risk of severe dengue disease. <i>Science</i> , 2020, 369, 1123-1128.	6.0	171
17	Inferring high-resolution human mixing patterns for disease modeling. <i>Nature Communications</i> , 2021, 12, 323.	5.8	161
18	The dengue vaccine pipeline: Implications for the future of dengue control. <i>Vaccine</i> , 2015, 33, 3293-3298.	1.7	109

#	ARTICLE	IF	CITATIONS
19	Immune correlates of protection for dengue: State of the art and research agenda. <i>Vaccine</i> , 2017, 35, 4659-4669.	1.7	81
20	A Frailty Mixture Model for Estimating Vaccine Efficacy. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 1996, 45, 165.	0.5	73
21	Estimating Efficacy of Trivalent, Cold-adapted, Influenza Virus Vaccine (CAIV-T) against Influenza A (H1N1) and B Using Surveillance Cultures. <i>American Journal of Epidemiology</i> , 2003, 158, 305-311.	1.6	72
22	Transmission dynamics of Ebola virus disease and intervention effectiveness in Sierra Leone. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4488-4493.	3.3	70
23	Community interventions and the epidemic prevention potential. <i>Vaccine</i> , 2002, 20, 3254-3262.	1.7	64
24	Simulations for designing and interpreting intervention trials in infectious diseases. <i>BMC Medicine</i> , 2017, 15, 223.	2.3	64
25	Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. <i>New England Journal of Medicine</i> , 2020, 382, 1366-1369.	13.9	63
26	Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave. <i>Nature</i> , 2021, 600, 127-132.	13.7	61
27	Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations. , 1998, 17, 1121-1136.		55
28	Containing Ebola at the Source with Ring Vaccination. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005093.	1.3	54
29	Assessing effects of cholera vaccination in the presence of interference. <i>Biometrics</i> , 2014, 70, 731-741.	0.8	50
30	Dependent Happenings: a Recent Methodological Review. <i>Current Epidemiology Reports</i> , 2016, 3, 297-305.	1.1	48
31	Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial. <i>PLoS Medicine</i> , 2017, 14, e1002282.	3.9	46
32	Household Transmission of <i>Vibrio cholerae</i> in Bangladesh. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3314.	1.3	45
33	Forecasting the effectiveness of indoor residual spraying for reducing dengue burden. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006570.	1.3	44
34	Projected Impact of Dengue Vaccination in Yucatán, Mexico. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004661.	1.3	44
35	Design of vaccine efficacy trials during public health emergencies. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	41
36	Interference and Sensitivity Analysis. <i>Statistical Science</i> , 2014, 29, 687-706.	1.6	37

#	ARTICLE	IF	CITATIONS
37	Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design. <i>Vaccine</i> , 2017, 35, 184-190.	1.7	37
38	Measuring vaccine efficacy from epidemics of acute infectious agents. <i>Statistics in Medicine</i> , 1993, 12, 249-263.	0.8	36
39	Identifying Areas with Elevated Disease Incidence Rates Using Empirical Bayes Estimators. <i>Geographical Analysis</i> , 1996, 28, 187-199.	1.9	36
40	Molecular Infectious Disease Epidemiology: Survival Analysis and Algorithms Linking Phylogenies to Transmission Trees. <i>PLoS Computational Biology</i> , 2016, 12, e1004869.	1.5	36
41	Estimating Vaccine Efficacy From Secondary Attack Rates. <i>Journal of the American Statistical Association</i> , 2003, 98, 38-46.	1.8	35
42	Quantifying the importance and location of SARS-CoV-2 transmission events in large metropolitan areas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	35
43	Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy. , 1998, 17, 185-200.		32
44	Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials. <i>Vaccine</i> , 2020, 38, 7213-7216.	1.7	32
45	Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term. <i>Science Translational Medicine</i> , 2021, 13, eabg9478.	5.8	32
46	The First Reported Outbreak of Chikungunya in the U.S. Virgin Islands, 2014â€“2015. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 885-889.	0.6	30
47	Spatiotemporal dynamics of the Ebola epidemic in Guinea and implications for vaccination and disease elimination: a computational modeling analysis. <i>BMC Medicine</i> , 2016, 14, 130.	2.3	30
48	Designing effective control of dengue with combined interventions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3319-3325.	3.3	29
49	Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine. <i>Clinical Infectious Diseases</i> , 2018, 66, 178-184.	2.9	28
50	Estimating the cost of illness and burden of disease associated with the 2014â€“2015 chikungunya outbreak in the U.S. Virgin Islands. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007563.	1.3	28
51	Empirical bayes estimators for spatially correlated incidence rates. <i>Environmetrics</i> , 1994, 5, 381-398.	0.6	27
52	Effects of infection history on dengue virus infection and pathogenicity. <i>Nature Communications</i> , 2019, 10, 1246.	5.8	26
53	Achieving coordinated national immunity and cholera elimination in Haiti through vaccination: a modelling study. <i>The Lancet Global Health</i> , 2020, 8, e1081-e1089.	2.9	26
54	School-Located Influenza Vaccination Reduces Community Risk for Influenza and Influenza-Like Illness Emergency Care Visits. <i>PLoS ONE</i> , 2014, 9, e114479.	1.1	25

#	ARTICLE	IF	CITATIONS
55	Comparative Effectiveness of Different Strategies of Oral Cholera Vaccination in Bangladesh: A Modeling Study. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3343.	1.3	24
56	A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines. , 1999, 18, 53-68.		23
57	One versus two doses: What is the best use of vaccine in an influenza pandemic?. <i>Epidemics</i> , 2015, 13, 17-27.	1.5	22
58	Epidemiology of dengue and other arboviruses in a cohort of school children and their families in Yucatan, Mexico: Baseline and first year follow-up. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006847.	1.3	22
59	Causal Inference for Vaccine Effects on Infectiousness. <i>International Journal of Biostatistics</i> , 2012, 8, 1-40.	0.4	21
60	Emerging, evolving, and established infectious diseases and interventions. <i>Science</i> , 2014, 345, 1292-1294.	6.0	18
61	Ebola and beyond. <i>Science</i> , 2015, 348, 46-48.	6.0	18
62	Estimating Strain-specific and Overall Efficacy of Polyvalent Vaccines Against Recurrent Pathogens From a Cross-sectional Study. <i>Biometrics</i> , 2013, 69, 235-244.	0.8	17
63	Meningococcal carriage within households in the African meningitis belt: A longitudinal pilot study. <i>Journal of Infection</i> , 2018, 76, 140-148.	1.7	17
64	The TIRS trial: protocol for a cluster randomized controlled trial assessing the efficacy of preventive targeted indoor residual spraying to reduce Aedes-borne viral illnesses in Merida, Mexico. <i>Trials</i> , 2020, 21, 839.	0.7	16
65	Effectiveness of Seasonal Influenza Vaccination in Children in Senegal During a Year of Vaccine Mismatch: A Cluster-randomized Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 1780-1788.	2.9	15
66	Seroprevalence of Dengue Antibodies in Three Urban Settings in Yucatan, Mexico. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 1202-1208.	0.6	14
67	Challenges of evaluating and modelling vaccination in emerging infectious diseases. <i>Epidemics</i> , 2021, 37, 100506.	1.5	14
68	Malaria vaccines: lessons from field trials. <i>Cadernos De Saude Publica</i> , 1994, 10, S310-S326.	0.4	13
69	Genomic epidemiology supports multiple introductions and cryptic transmission of Zika virus in Colombia. <i>BMC Infectious Diseases</i> , 2019, 19, 963.	1.3	12
70	Successes and Failures of the Live-attenuated Influenza Vaccine: Can We Do Better?. <i>Clinical Infectious Diseases</i> , 2020, 70, 1029-1037.	2.9	12
71	Disseminated Effects in Agent-Based Models: A Potential Outcomes Framework and Application to Inform Preexposure Prophylaxis Coverage Levels for HIV Prevention. <i>American Journal of Epidemiology</i> , 2021, 190, 939-948.	1.6	12
72	Estimating population effects of vaccination using large, routinely collected data. <i>Statistics in Medicine</i> , 2018, 37, 294-301.	0.8	11

#	ARTICLE	IF	CITATIONS
73	Quantifying the risk of local Zika virus transmission in the contiguous US during the 2015â€“2016 ZIKV epidemic. BMC Medicine, 2018, 16, 195.	2.3	11
74	Comparing Biomarkers as Trial Level General Surrogates. Biometrics, 2016, 72, 1046-1054.	0.8	9
75	Dengue seroprevalence in a cohort of schoolchildren and their siblings in Yucatan, Mexico (2015-2016). PLoS Neglected Tropical Diseases, 2018, 12, e0006748.	1.3	9
76	Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial. BMC Infectious Diseases, 2018, 18, 84.	1.3	9
77	Semiparametric Methods for Multiple Exposure Mismeasurement and a Bivariate Outcome in HIV Vaccine Trials. Biometrics, 1999, 55, 94-101.	0.8	8
78	Intermediate levels of vaccination coverage may minimize seasonal influenza outbreaks. PLoS ONE, 2018, 13, e0199674.	1.1	8
79	Impact of Rotavirus Vaccine Introduction in Children Less Than 2 Years of Age Presenting for Medical Care With Diarrhea in Rural Matlab, Bangladesh. Clinical Infectious Diseases, 2019, 69, 2059-2070.	2.9	8
80	Semi-parametric models for mismeasured exposure information in vaccine trials. , 1998, 17, 2335-2352.		6
81	Design of vaccine trials during outbreaks with and without a delayed vaccination comparator. Annals of Applied Statistics, 2018, 12, 330-347.	0.5	6
82	Estimates of Inactivated Influenza Vaccine Effectiveness Among Children in Senegal: Results From 2 Consecutive Cluster-Randomized Controlled Trials in 2010 and 2011. Clinical Infectious Diseases, 2021, 72, e959-e969.	2.9	6
83	Protecting the herd with vaccination. Science, 2022, 375, 1088-1089.	6.0	6
84	Estimands and inference in clusterâ€“randomized vaccine trials. Pharmaceutical Statistics, 2020, 19, 710-719.	0.7	5
85	Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies. Vaccine, 2016, 34, 3796-3802.	1.7	4
86	Cost-effectiveness of live-attenuated influenza vaccination among school-age children. Vaccine, 2021, 39, 447-456.	1.7	4
87	Improving adolescent human papillomavirus (HPV) immunization uptake in school-based health centers through awareness campaigns. Vaccine, 2021, 39, 1765-1772.	1.7	4
88	An Assessment of Household and Individual-Level Mosquito Prevention Methods during the Chikungunya Virus Outbreak in the United States Virgin Islands, 2014â€“2015. American Journal of Tropical Medicine and Hygiene, 2018, 98, 845-848.	0.6	4
89	The case for a typhoid vaccine probe study and overview of design elements. Vaccine, 2015, 33, C30-C35.	1.7	3
90	Optimizing and evaluating biomarker combinations as trialâ€“level general surrogates. Statistics in Medicine, 2019, 38, 1135-1146.	0.8	3

#	ARTICLE	IF	CITATIONS
91	Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions. <i>Annals of Internal Medicine</i> , 2020, 173, 576-577.	2.0	3
92	Inverse probability weighted estimators of vaccine effects accommodating partial interference and censoring. <i>Biometrics</i> , 2022, 78, 777-788.	0.8	3
93	Using simulated infectious disease outbreaks to inform site selection and sample size for individually randomized vaccine trials during an ongoing epidemic. <i>Clinical Trials</i> , 2021, 18, 630-638.	0.7	3
94	Reply to Aguiar and Stollenwerk. <i>Clinical Infectious Diseases</i> , 2018, 66, 642-642.	2.9	2
95	Validity of university students' self-reported vaccination status after a meningococcal B outbreak. <i>Journal of American College Health</i> , 2020, , 1-6.	0.8	2
96	Comment on AIDS and COVID-19: A tale of two pandemics and the role of statisticians. <i>Statistics in Medicine</i> , 2021, 40, 2524-2525.	0.8	2
97	Discussion on "Estimating vaccine efficacy over time after a randomized study is unblinded" by Anastasios A. Tsiatis and Marie Davidian. <i>Biometrics</i> , 2022, 78, 839-840.	0.8	2
98	A Bayesian approach to estimating causal vaccine effects on binary post-infection outcomes. <i>Statistics in Medicine</i> , 2016, 35, 53-64.	0.8	1
99	Reply to Skowronski and De Serres. <i>Clinical Infectious Diseases</i> , 2019, 69, 2231-2232.	2.9	1
100	Estimating population-level effects of the acellular pertussis vaccine using routinely collected immunization data. <i>Clinical Infectious Diseases</i> , 2021, 73, 2101-2107.	2.9	1
101	Evaluation and comparison of predictive individual-level general surrogates. <i>Biostatistics</i> , 2018, 19, 307-324.	0.9	0
102	Reply to Lindsey, Hirschler, and de Silva. <i>Clinical Infectious Diseases</i> , 2020, 70, 2236-2237.	2.9	0
103	Comment on Laber et al. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2018, 67, 776.	0.5	0